Published On: Wed, Nov 1st, 2017

New Analyst Ratings On Tonix Pharmaceuticals Holding Corp. (TNXP)


Recently stock market analysts have updated their consensus ratings on shares of Tonix Pharmaceuticals Holding Corp. (TNXP).

Most recent broker ratings

08/22/2017 – Dawson James began new coverage on Tonix Pharmaceuticals Holding Corp. giving the company a “buy” rating. They now have a USD 9 price target on the stock.

08/18/2017 – Tonix Pharmaceuticals Holding Corp. was upgraded to “buy” by analysts at Roth Capital. They now have a USD 6 price target on the stock.

06/26/2017 – Aegis Capital began new coverage on Tonix Pharmaceuticals Holding Corp. giving the company a “buy” rating. They now have a USD 10 price target on the stock.

12/19/2016 – Tonix Pharmaceuticals Holding Corp. had its “perform” rating reiterated by analysts at Oppenheimer.

09/07/2016 – Tonix Pharmaceuticals Holding Corp. was downgraded to “hold” by analysts at Cantor Fitzgerald. They now have a USD 1 price target on the stock.

06/29/2015 – Tonix Pharmaceuticals Holding Corp. had its “buy” rating reiterated by analysts at Janney Montgomery Scott. They now have a USD 12 price target on the stock.

01/26/2015 – Tonix Pharmaceuticals Holding Corp. had its “neutral” rating reiterated by analysts at Zacks. They now have a USD 10 price target on the stock.

Tonix Pharmaceuticals Holding Corp. has a 50 day moving average of 4.26 and a 200 day moving average of 4.09. The stock’s market capitalization is 27.79M, it has a 52-week low of 2.85 and a 52-week high of 9.40.

The share price of the company (TNXP) was down -3.61% during the last trading session, with a high of 3.98 and the volume of Tonix Pharmaceuticals Holding Corp. shares traded was 50365.